TWYNSTA
LOE ApproachingNDAORALTABLET
Approved
Oct 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TWYNSTA is an oral tablet approved in 2009 for hypertension, a cardiovascular condition affecting millions globally. The drug's mechanism of action is not specified in available data, but it competes in a crowded antihypertensive market dominated by ARBs, ACE inhibitors, and calcium channel blockers. It is a small-molecule therapeutic developed and marketed by Boehringer Ingelheim.
LOE Approaching
As LOE approaches, the brand team is likely focused on retention and cost-optimization strategies; headcount and hiring may be limited or shifting toward generic support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
Started Mar 2011
2,089 enrolled
Hypertension
A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
Started Dec 2010
674 enrolled
Hypertension
Career Relevance
Working on TWYNSTA as LOE approaches offers limited career growth potential and likely smaller team size compared to growth-stage products. Opportunities are concentrated in defensive commercial roles (managed-care negotiations, patient retention, generic preparation) rather than brand-building or development roles.
Worked on TWYNSTA at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.